This site is intended for healthcare professionals

COPD experts tackle key topics in our latest Q&A

Read time: 1 mins
Last updated:7th Mar 2019
Published:7th Mar 2019
Source: Pharmawand

We've recently added some quick-fire questions from the COPD Spotlight Webinar on the topic of "Can we avoid inhaled corticosteroid dependence (ICS) in COPD? Time for clarity". The full Q&A can be found here, or select your question below to read our expert's insights.

Professor Wisia Wedzicha and Dr Kai Beeh tackle five frequently asked questions. 

Question 1

A patient receiving triple therapy moves from Global initiative for chronic Obstructive Lung Disease (GOLD) group D to B. Should we re-evaluate this patient every 12 months or leave him/her on triple therapy because inhaled corticosteroid (ICS) dependency was previously shown?



Question 2

If a patient is in Global initiative for chronic Obstructive Lung Disease (GOLD) group D and is stable on long acting β2 agonist/long-acting muscarinic antagonist (LABA/LAMA), but their eosinophil level is above 300 cells/µL, should we escalate to triple therapy or not?



Question 3

Is one long acting β2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination superior to others and why?



Question 4

Does a high eosinophil count indicate asthma-COPD overlap (ACO)?



Question 5

Would you measure blood eosinophils in non-frequently exacerbating patients? If yes, would you make a distinction between patients with 0 and 1 exacerbation in your approach?



Visit the full COPD Learning Zone


Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.